Wedbush Reiterates Outperform on Aclaris Therapeutics, Maintains $8 Price Target

Benzinga Newsdesk www.benzinga.com Negative 73.6%

Neg 73.6% Neu 0% Pos 0%

Wedbush analyst Martin Fan reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and maintains $8 price target.